Posts tagged TBP
Tetra Bio-Pharma updates Dronabinol XL AdVersa development plans

Tetra Bio-Pharma (TSXV:TBP; OTCQB:TBPMF) is partnering with a major manufacturer of controlled active pharmaceutical ingredients in the U.S. to  manufacture Dronabinol XL AdVersa as part of the company’s plans to submit a 505(b)(2) NDA for the treatment of chemotherapy-induced nausea and vomiting and anorexia associated with weight loss in patients with AIDS.

Read More
Tetra Bio-Pharma names Bernard Fortier as CEO

Tetra BioPharma (OTCQB:TBPMF; CSE:TBP) appointed Bernard Fortier to the position of CEO, effective July 24. 

Read More
Tetra in cannabis pact with Constance Therapeutics

Tetra Bio-Pharma (OTCQB:TBPMF; CSE:TBP) has signed a letter of intent with Constance Therapeutics of San Francisco for the clinical development and commercialization in Canada of its signature medicinal cannabis extract products.

Read More
Tetra, New Brunswick to collaborate on cannabis research

Tetra Bio-Pharma (OTCQB:TBPMF; CSE:TBP) and the New Brunswick Health Research Foundation are investing $500,000 each over five years to establish a health research chair in cannabis at the University of New Brunswick.

Read More
Tetra readies Phase 3 pain relief trial of medical cannabis

Tetra Bio-Pharma (CSE:TBP; OTCQB:TBPMF) and subsidiary, PhytoPain Pharma, have submitted a report on the safety and pharmacokinetics of its PPP001 smokeable cannabis product to Health Canada.

Read More
IntelGenx, Tetra to develop Dronabinol XL tablet

IntelGenx (OTCQX:IGXT; TSXV:IGX) and Tetra Bio-Pharma (CSE:TBP; OTC:GRPOF) signed a definitive agreement to develop and commercialize a drug product containing the cannabinoid, Dronabinol, for the management of anorexia and cancer chemotherapy-related pain.

Read More
IntelGenx, Tetra in development term sheet

IntelGenx (TSX-V:IGX; OTCQX:IGXT) and Tetra Bio-Pharma (CSE:TBP; OTC: GRPOF) announced the signing of a binding term sheet for the development and commercialization of a drug product containing dronabinol.

Read More